换一批
换一批Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
第一作者：
Michael A,Nauck
第一单位：
Diabetes, Endocrinology and Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, St. Josef-Hospital, Ruhr-University Bochum, Gudrunstr. 56, 44791, Bochum, Germany. michael.nauck@rub.de.
作者：
主题词
体重(Body Weight);心血管疾病(Cardiovascular Diseases);临床试验(主题)(Clinical Trials as Topic);糖尿病, 2型(Diabetes Mellitus, Type 2);肠抑胃肽(Gastric Inhibitory Polypeptide);胰高血糖素样肽1(Glucagon-Like Peptide 1);人类(Humans);降血糖药(Hypoglycemic Agents);胰岛素(Insulin);Meta分析(主题)(Meta-Analysis as Topic);体重减轻(Weight Loss)
DOI
10.1186/s12933-022-01604-7
PMID
36050763
发布时间
2025-01-03
- 浏览5
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
